Tyra Biosciences, Inc.
TYRA$1.77B
Small CapNASDAQPharmaceutical Preparations🇺🇸North AmericaCARLSBAD60 employees
Drugs in Pipeline
4
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Nov 15, 2026
35wMarket Overview
Stock performance and key metrics
TYRA News
Catalyst Timeline
1 upcoming, 1 past
Drug Pipeline
TYRA-300 60mg
Low-grade NMIBC
TYRA-300
Locally Advanced Urothelial Carcinoma
TYRA-300 0.125 mg/kg
Achondroplasia
Dabogratinib (TYRA-300) 60mg
Low Grade Upper Tract Urothelial Carcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
TYRA-300 60mg | Phase 2 | Low-grade NMIBC | - | - |
TYRA-300 | Phase 2 | Locally Advanced Urothelial Carcinoma | - | - |
TYRA-300 0.125 mg/kg | Phase 2 | Achondroplasia | - | - |
Dabogratinib (TYRA-300) 60mg | Phase 2 | Low Grade Upper Tract Urothelial Carcinoma | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply